Immunic, Inc.

NasdaqGS IMUX

Immunic, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Immunic, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Immunic, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -62.39%, a -15.77% change year over year.
Immunic, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -53.90%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGS: IMUX

Immunic, Inc.

CEO	Dr. Daniel Vitt Ph.D.
IPO Date	April 17, 2014
Location	United States
Headquarters	1200 Avenue of the Americas
Employees	85
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Key trends

Past 5 years